Also trades as: LUN.CO (CPH) · $vol 10M · HLUN-B.CO (CPH) · $vol 4M · HLUN-A.CO (CPH) · $vol 1M · HLUYY (OTC) · $vol 0M · HLBBF (OTC) · $vol 0M
HLUBF OTC
H. Lundbeck A/S
1W: +0.0%
1M: +15.5%
3M: +16.4%
YTD: +19.6%
1Y: +17.0%
3Y: +47.5%
$6.40
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$6.8B
52W Range4.82-6.79
Volume1
Avg Volume62
Beta0.26
Dividend$0.18
Analyst Ratings
No analyst coverage
Company Info
CEOCharl van Zyl
Employees5,214
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2022-07-18
Websitelundbeck.com
Ottiliavej 9
Valby, CR 2500
DK
Valby, CR 2500
DK
45 36 30 13 11
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Operations. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
Recent Insider Trades
No insider trades found